Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH.
Journal: Cell metabolism
Published: March 26, 2025
ACLY inhibition promotes tumour immunity and suppresses liver cancer.
Journal: Nature
Published: May 10, 2023
Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis development.
Journal: Frontiers in cardiovascular medicine
Published: June 02, 2022
Corrigendum to "Discovery of analogues of non-β oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism" [Nutr Metabol Cardiovasc Dis 31 (2021) 2490-2703].
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD
Published: December 11, 2021
Discovery of analogues of non-β oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism.
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD
Published: February 23, 2021
Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+/- and LDLR-/-) Yucatan Miniature Pigs.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: October 03, 2017
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: October 06, 2016
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
Journal: Journal of clinical lipidology
Published: October 22, 2015
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Journal: Journal of clinical lipidology
Published: September 24, 2014
LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase.
Journal: Current opinion in lipidology
Published: July 01, 2014
Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: January 04, 2014
Last Updated: 09/26/2026